Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $38.00 price objective on the stock. A number of other research analysts also recently issued reports on the stock. StockNews.com downgraded shares of Protagonist Therapeutics from a […]

Related Keywords

Hong Kong ,Canada , ,Jpmorgan Chase Co ,Proshare Advisors ,Protagonist Therapeutics Company Profile ,Ameritas Investment Partners Inc ,Tower Research Capital ,Hong Kong Ltd ,Protagonist Therapeutics Inc ,Royal Bank ,Protagonist Therapeutics ,Free Report ,Get Free Report ,Research Capital ,Investment Partners ,Kong Ltd ,Protagonist Therapeutics Daily ,Nasdaq Ptgx ,Ptgx ,Medical ,Reiterated Rating ,Hc Wainwright ,